Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06516302

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are:

1. Does GR1802 reduce the need for surgery and systemic corticosteroid use？ 2. What medical problems do participants have when taking GR1802?

Researchers will compare GR1802 to a placebo (a look-alike substance that contains no drug) to see if GR1802 works to treat CRSwNP.

Participants will:

Take GR1802 or a placebo once every 2 weeks for 13months. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms and the dosage and number of times they use mometasone furoate nasal spray.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing Tongren Hospital, Capital Medical University

Beijing, China

About this study

A randomized, double-blind, placebo-controlled, multi-center clinical trial was designed. The clinical trial was divided into 4 stages: screening/introduction period, double-blind treatment period , maintenance treatment period and safety follow-up period.

The clinical trial aimed to evaluate the efficacy, safety and immunogenicity of GR1802 injection in CRSwNP participants.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed as CRSwNP and treated with systemic glucocorticoid within 2 years before screening; and/or those who had undergone surgery for nasal polyps before screening.
  • An endoscopic bilateral NPS at screening/lead-in period and the baseline period of at least 5 out of a maximum score of 8 (with a minimum socre of 2 in each nasal cavity).
  • Nasal congestion/blockade/obstruction with moderate or severe symptom severity at at screening period (score 2 or 3 ) .
  • Willing to sign an informed consent, able to comply with clinic visits and study-related procedures as per protocol.

Exclusion criteria

  • Biologic therapy within 5 half-lives or within 10 weeks before baseline.
  • Anti-IL-4Rα antibody before screening.
  • An experimental drug within 5 half-lives or 1 months before baseline.
  • Systemic immunosuppressant to treat inflammatory disease or autoimmune disease within 2 months or 5 half-lives before baseline.
  • Initiation of allergen immunotherapy within 3 months before screening.
  • Participants receiving leukotriene antagonist/modifier before screening unless on continous treatment for at least 30 days.
  • Participants with FEV1 50% or less of predicted normal were excluded.
  • Participants who have undergone any intranasal and/or sinus surgery within 6 months before screening.
  • Acute sinusitis or upper respiratory infection within a defined time period before screening.
  • A nasal cavity tumor (malignant or benign).
  • Evidence of fungal rhinosinusitis.
  • Presence of another diagnosis associated with nasal polyps (i.e., eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, Young's syndrome, cystic fibrosis).
  • Rhinitis medicamentosa.
  • Nasal septal deviation occluding at least one nostril.
  • Antrochoanal polyps.
  • Pregnant or lactating woman.

Treatment and study plan

GR1802

Drug

GR1802 will be administered SC.

Placebo

Drug

The placebo will be administered SC.

Primary outcomes

  1. Change from baseline in nasal polyps score at week 24.

    Time frame: At week 24

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

  2. Change from baseline in nasal congestion score at week 24.

    Time frame: At week 24

    Nasal congestion score (0-3), higher score means worse nasal symptom.

Secondary outcomes

  1. Change from baseline in reduction/loss of smell at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.

    Time frame: From baseline to week 60

    The reduction/loss of smell severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse sense of smell.

  2. Change from baseline in nasal discharge (anterior/posterior) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.

    Time frame: From baseline to week 60

    The nasal discharge severity was reported by the participant on a daily basis using a 0 to 3 categorical scale. Higher score means a worse nasal symptom.

  3. Change from baseline in Total Nasal Symptom Score (TNSS) at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 and 60.

    Time frame: From baseline to week 60

    TNSS score (0-9). Higher score means worse nasal symptom.

  4. Change from baseline in nasal endoscopy nasal polyps score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.

    Time frame: At week 24

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

  5. Change from baseline in nasal congestion score in participants with a high power field of vision < 55 eosinophil granulocytes in nasal polyp tissue at week 24.

    Time frame: At week 24

    Nasal congestion score (0-3), higher score means worse nasal symptom.

  6. Change from baseline in nasal polyps score at weeks 2、4、8、16、32、40、52 and 60.

    Time frame: From baseline to week 60

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

  7. Proportion of participants with improvement by at least 1 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.

    Time frame: From baseline to week 60

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

  8. Proportion of participants with improvement by at least 2 point in nasal polyps score at weeks 2、4、8、16、24、32、40、52 and 60.

    Time frame: From baseline to week 60

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

  9. Time to first response (≥1 point improvement) in nasal polyps score.

    Time frame: From baseline to week 60

    Nasal polyps score score ranges from 0-8 (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

  10. Change from baseline in nasal congestion score at weeks 4、8、12、16、20、28、32、36、40、44、48、52、56 and 60.

    Time frame: From baseline to week 60

    Nasal congestion score (0-3), higher score means worse nasal symptom.

  11. Proportion of participants with improvement by at least 1 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.

    Time frame: From baseline to week 60

    Nasal congestion score (0-3), higher score means worse nasal symptom.

  12. Proportion of participants with improvement by at least 2 point in nasal congestion score at weeks 4、8、12、16、20、24、28、32、36、40、44、48、52、56 and 60.

    Time frame: From baseline to week 60

    Nasal congestion score (0-3), higher score means worse nasal symptom.

  13. Change from baseline in Lund-Mackay score at week 24 and 52.

    Time frame: From baseline to week 60

    The range of LM score is 0-24. Higher score means worse rhinosinusitis.

  14. Change from baseline in 22-item Sinonasal Outcome Test (SNOT-22) at weeks 2, 4, 8, 16, 24, 32, 40, 52 and 60.

    Time frame: From baseline to week 60

    The range of SNOT-22 score is 0 to 110. Higher scores indicating more severe disease.

  15. Change from baseline in University of Pennsylvania Smell Identification Test (UPSIT) at weeks 2, 4, 16, 24, 32, 40, 52 and 60.

    Time frame: From baseline to week 60

    UPSIT score (0-40). Higher score means better sense of smell.

  16. Change from baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) at weeks 4、16、24、40、52 and 60.

    Time frame: From baseline to week 60

    The EQ-5D-5L descriptive system comprises five dimensions (MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION), and each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. The respondent is asked to indicate his/her health state by checking the box next to the most appropriate response level for each of the five dimensions.

  17. Safety parameters.

    Time frame: From baseline to week 60

    Incidence of treatment-emergent adverse events (TEAEs), incidence of treatment-emergent serious AEs (TESAEs), etc.

  18. Pharmacokinetics, include Ctrough, etc.

    Time frame: From baseline to week 60

    GR1802 concentrations were measured in CRSwNP population using sparse sampling (samples collected at predose, during treatment, and the follow up period).

  19. Pharmacodynamics.

    Time frame: From baseline to week 60

    Levels of the type 2 inflammation biomarkers were assessed as markers for disease activity/severity.

  20. Immunogenicity, include ADA and Nab.

    Time frame: From baseline to week 60

    Anti GR1802 antibody status was determined at baseline and at prespecified time points.

Sponsors and collaborators

Lead sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of GR1802 in Participants With Chronic Rhinosinusitis With Nasal Polyps

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jul 23, 2024
Registry last updated
Mar 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.